Biosimilar Update: Fresenius’ Actemra Biosimilar Now Available in the US
Fresenius’ Tyenne (tocilizumab-aazg), a biosimilar of Actemra (tocilizumab), is now available for use in the US. Tyenne is the first tocilizumab biosimilar with an intravenous and subcutaneous formulation approved by the FDA. The biosimilar received FDA approval on March 5, 2024. Tyenne is Fresenius’ third approved biosimilar available in the U.S. and the second within […]